Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2009
Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 95 citations in OpenAlex.
- Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2011Trial
- Pharmacogenetics studies in STAR*D: strengths, limitations, and results.Psychiatric services (Washington, D.C.) · 2009Trial
- Sexual dysfunction associated with antidepressants and antipsychotics: a structured narrative review of mechanisms, assessment, and personalized management.Frontiers in psychiatry · 2026Review
- Paraphilic disorders, psychopathy, and those who sexually offend: a narrative review of treatment modalities.International journal of impotence research · 2025Review
- Insufficient correctness of package inserts for psychotropic drugs in Germany.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date.Drug design, development and therapy · 2021Review
- TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients.Molecular biology reports · 2020Article
- Association between serotonin 2A receptor (HTR2A), serotonin transporter (SLC6A4) and brain-derived neurotrophic factor (BDNF) gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients.The pharmacogenomics journal · 2020Observational
- Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives.Neuropsychiatric disease and treatment · 2020Review
- GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment reponses in Chinese of Han ethnicity.Medicine · 2019Article
- Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?Endocrine · 2018Review
- Delayed Ejaculation: Pathophysiology, Diagnosis, and Treatment.The world journal of men's health · 2018Review
- A Model for the Management of Female Sexual Dysfunctions.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2017Review
- BDNF-GSK-3β-β-Catenin Pathway in the mPFC Is Involved in Antidepressant-Like Effects of Morinda officinalis Oligosaccharides in Rats.The international journal of neuropsychopharmacology · 2017Article
- Sexual Function Across Aging.Current psychiatry reports · 2016Review
- A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2014Article
- From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2014Review
- Study of effects of selective serotonin reuptake inhibitors on stages of sexual function in Iranian patients with major depressive disorder.Therapeutic advances in psychopharmacology · 2013Article
- A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual men.Therapeutic advances in urology · 2013Article
- Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction.Psychiatry research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Sexual dysfunction is a major contributor to treatment discontinuation and nonadherence among patients treated with selective serotonin reuptake inhibitors (SSRIs). The mechanisms by which depressive symptoms in general, as well as SSRI exposure in particular, may worsen sexual function are not known. We examined genetic polymorphisms, including those of the serotonin and glutamate systems, for association with erectile dysfunction, anorgasmia, and decreased libido during citalopram treatment. Clinical data were drawn from a nested case-control cohort derived from the STAR(*)D study, a multicenter, prospective, effectiveness trial in outpatients with nonpsychotic major depressive disorder (MDD). Self-reports of erectile dysfunction, decreased libido, or difficulty achieving orgasm based on the Patient-Rated Inventory of Side Effects were examined among Caucasian subjects (n=1473) for whom DNA and adverse effect measures were available, and who were treated openly with citalopram for up to 14 weeks. Of 1473 participants, 799 (54%) reported decreased libido; 525 (36%) reported difficulty achieving orgasm. Of 574 men, 211 (37%) reported erectile dysfunction. Using a set-based test for association, single nucleotide polymorphisms in glutamatergic genes were associated with decreased libido (GRIA3; GRIK2), difficulty achieving orgasm (GRIA1), and difficulty achieving erection (GRIN3A) (experiment-wide permuted p<0.05 for each). Evidence of association persisted after adjustment for baseline clinical and sociodemographic differences. Likewise, evidence of association was similar when the cohort was limited to those who did not report a given adverse event at the first post-baseline visit (ie, those whose adverse events were known to be treatment emergent). These hypothesis-generating analyses suggest the potential for glutamatergic treatment targets for sexual dysfunction during major depressive episodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.